Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14759636 | 1.00 | LPAR2 (0.42) | LPAR2LPAR3LPAR1FAAHTRPV1 | |
| SCHEMBL2724494 | 1.00 | LPAR2 (0.42) | LPAR2LPAR3LPAR1FAAHTRPV1 | |
| SCHEMBL15209157 | 1.00 | LPAR2 (0.42) | LPAR2LPAR3LPAR1FAAHTRPV1 | |
| SCHEMBL15472172 | 1.00 | LPAR2 (0.42) | LPAR2LPAR3LPAR1FAAHTRPV1 | |
| SCHEMBL4561383 | 1.00 | LPAR2 (0.42) | LPAR2LPAR3LPAR1FAAHTRPV1 | |
| SCHEMBL14889709 | 1.00 | LPAR2 (0.42) | LPAR2LPAR3LPAR1FAAHTRPV1 | |
| SCHEMBL14900455 | 1.00 | LPAR2 (0.42) | LPAR2LPAR3LPAR1FAAHTRPV1 | |
| SCHEMBL2724499 | 1.00 | LPAR2 (0.42) | LPAR2LPAR3LPAR1FAAHTRPV1 | |
| SCHEMBL15472141 | 1.00 | LPAR2 (0.42) | LPAR2LPAR3LPAR1FAAHTRPV1 | |
| SCHEMBL15472173 | 1.00 | LPAR2 (0.42) | LPAR2LPAR3LPAR1FAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635265-A2 | NOVEL LOW MOLECULAR WEIGHT CYCLIC AMINE CONTAINING CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | Merck Sharp & Dohme Corp. (US) | 2013-09-11 | — | — | EP | claimed |
| WO-2012061259-A2 | NOVEL LOW MOLECULAR WEIGHT CYCLIC AMINE CONTAINING CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2012-05-10 | — | — | WO | claimed |
| CN-118317944-A | Acyclic lipids and methods of use thereof | 雷纳嘉德医疗管理公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118234707-A | Cyclic lipids and methods of use thereof | 雷纳嘉德医疗管理公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2024073848-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2024-04-11 | — | — | WO | disclosed |
| WO-2023220387-A2 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023196931-A1 | CYCLIC LIPIDS AND LIPID NANOPARTICLES (LNP) FOR THE DELIVERY OF NUCLEIC ACIDS OR PEPTIDES FOR USE IN VACCINATING AGAINST INFECTIOUS AGENTS | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023137550-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023115221-A1 | IONIZABLE DILSULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023050003-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023044343-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023044333-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023023055-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-10337014-B2 | Low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180037893-A1 | NOVEL LOW MOLECULAR WEIGHT CYCLIC AMINE CONTAINING CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-9067882-B2 | Low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067882-B2 | Low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130225836-A1 | NOVEL LOW MOLECULAR WEIGHT CYCLIC AMINE CONTAINING CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225836-A1 | NOVEL LOW MOLECULAR WEIGHT CYCLIC AMINE CONTAINING CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225836-A1 | NOVEL LOW MOLECULAR WEIGHT CYCLIC AMINE CONTAINING CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | LDLR, APOB, CETP | LPAR2 25/4885LPAR3 5/4885LPAR1 14/4885 |
| US-10337014-B2 | Low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery | LDLR, APOB, CETP | LPAR2 18/4885LPAR3 4/4885LPAR1 13/4885 |
| US-20180037893-A1 | NOVEL LOW MOLECULAR WEIGHT CYCLIC AMINE CONTAINING CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | LDLR, APOB, CETP | LPAR2 25/4885LPAR3 5/4885LPAR1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.